Email: ielsg@ior.usi.ch /
Phone: + 41 58 666 73 04/05/06
LATEST NEWS
- We have moved
NEW ADDRESS (as of 25.07.2022)
IELSG Headquarters
Foundation for the Institute of Oncology Research (IOR)
Via Vincenzo Vela, 6
CH-6500 Bellinzona
Phone + 41 58 666 73 21
ielsg@ior.usi.ch - Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
Reference Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Link Author(s) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Study IELSG32
ONGOING STUDIES
- IELSG49IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
- IELSG44IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
- IELSG47 StudyMALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
LATEST NEWSLETTER
- Newsletter Number 53
Click here to open the pdf file – Click here to read the newsletter in HTML
- Newsletter Number 52
PUBLICATIONS
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialReference Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Link Author(s) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, […]
- Genetic and phenotypic attributes of splenic marginal zone lymphomaReference Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. Link Author(s) Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, […]